このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Andy's Mind: A Co-created Serious Game for People With Psychosis (PSICOGAME) (PSICOGAME)

2026年11月12日 更新者:Fundació Sant Joan de Déu

Development and Evaluation of the Effectiveness of a Psychoeducational Serious Game for People With Schizophrenia Spectrum and Other Psychotic Disorders

The goal of this clinical trial is to learn whether Andy's Mind, a psychoeducational card game co-created with a person with lived experience of psychosis, improves illness awareness (insight) and attitudes toward treatment in adults with schizophrenia spectrum and other psychotic disorders, compared with conventional group psychoeducation.

The main questions it aims to answer are:

  • Does Andy's Mind improve insight into mental disorder more than conventional psychoeducation?
  • Does Andy's Mind improve attitudes toward medication, as an indicator of treatment adherence, more than conventional psychoeducation?

Researchers will also look at psychotic symptoms, attitudes toward alcohol and other drugs, and participant satisfaction.

Participants will:

  • Be randomly assigned to one of two groups: the Andy's Mind game group or a conventional psychoeducation group.
  • Attend 8 weekly group sessions of 45 minutes. Both groups cover the same topics: what psychosis is, symptoms, treatment, side effects, substance use and relapse prevention.
  • Complete interviews and questionnaires before the sessions, right after the last session, and two months later.

The study takes place in mental health services in Catalonia, Spain, including prison mental health units, psychosocial rehabilitation services and community mental health centers.

調査の概要

詳細な説明

Background Poor insight and low adherence to antipsychotic treatment are common in people with psychotic disorders and are associated with relapse and rehospitalization. Group psychoeducation is an evidence-based intervention that improves illness awareness and adherence, but many patients have difficulty understanding and integrating the information delivered in conventional formats, particularly in settings with cognitive, language and cultural barriers such as prison mental health units. Serious games may increase intrinsic motivation, participation and peer interaction, and reduce the hierarchical structure of conventional psychoeducation. To date, no analog serious game for psychoeducation in psychosis has been evaluated in a randomized controlled trial.

Intervention development The study has two phases. In Phase 1, Andy's Mind was developed through participatory co-design with mental health professionals and a person with lived experience of psychosis, who also illustrated the cards, and was tested in a usability pilot in two prison mental health units (n=10). Phase 1 participants are not eligible for Phase 2. This registration corresponds to Phase 2, the randomized controlled trial.

Experimental intervention Andy's Mind is an analog card game for 2 to 6 players. It uses a science-fiction narrative in which psychotic symptoms are represented as creatures that players learn to stabilize using treatment and protective factors while facing relapse risks such as substance use or sleep deprivation. The final version includes 104 cards in seven categories (symptom, treatment, side effect, protection, attack/relapse, boom and wild cards), with images and text in Spanish, English and Arabic and high-contrast color coding. The intervention consists of 8 weekly group sessions of 45 minutes with 4 to 6 participants: sessions 1 and 2 introduce the rules and the meaning of each card, and sessions 3 to 8 consist of gameplay followed by 5 to 10 minutes of questions to check understanding. Sessions are led by mental health professionals trained by the research team using a facilitator manual.

Active comparator Conventional group psychoeducation based on the PIENSA program, with the same dose (8 weekly sessions of 45 minutes, groups of 4 to 8 participants) and the same content: what psychosis is (session 1), symptoms (sessions 2 and 3), treatments (session 4), side effects (session 5), drugs and psychosis (session 6), relapse prevention, protective and precipitating factors (session 7), and review (session 8).

Design and randomization Multicenter, two-arm, parallel-group, open-label randomized controlled trial. Eighty participants (40 per arm) are recruited by consecutive sampling. Allocation follows a randomization sequence generated by a person external to the research team and linked to the consecutive participant code. Assessments are carried out by members of the research team who do not deliver the interventions; assessors are not blinded to group allocation.

Assessments Participants are assessed at baseline (T0), immediately after the 8-session intervention (T1) and at a 2-month follow-up (T2). Cognitive screening with the SCIP-S is performed at baseline only, as an exclusion criterion. Sociodemographic and clinical data, including a descriptive substance use questionnaire, are collected at baseline. Questionnaires are completed on paper or directly in REDCap depending on device availability and unit regulations; paper data are transcribed into REDCap by the principal investigator.

Sample size and analysis With alpha 0.05 (one-sided) and 80% power, 80 participants allow detection of an effect size of Cohen's d = 0.63 in the between-group comparison at T1 using ANCOVA adjusted for baseline scores, assuming a pre-post correlation of 0.2. The main analysis follows the intention-to-treat principle and compares groups at T1 and T2 with ANCOVA adjusted for baseline values. Care setting (prison, community, rehabilitation) will be considered as a covariate. Change over time will also be explored with repeated-measures or linear mixed models including group, time and group-by-time interaction. A per-protocol analysis will be performed as a complementary analysis.

研究の種類

介入

入学 (推定)

80

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Andrea Fontán Abeijón, RN, BSc
  • 電話番号:+34687343637
  • メール:andrea.fontan@sjd.es

研究連絡先のバックアップ

研究場所

    • Barcelona
      • Sant Boi de Llobregat、Barcelona、スペイン、08830
        • 募集
        • Parc Sanitari Sant Joan de Déu
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Andrea Fontán Abeijón, RN, BSc

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Adults aged 18 to 65 years, inclusive.
  • Diagnosis within the schizophrenia spectrum and other psychotic disorders according to DSM-5: schizophrenia, schizoaffective disorder, delusional disorder, brief psychotic disorder, schizophreniform disorder, substance/medication-induced psychotic disorder, psychotic disorder due to another medical condition, or unspecified psychotic disorder.
  • Receiving care in a prison, community or rehabilitation mental health service.
  • Signed informed consent from the participant and, when applicable, from the legal guardian.

Exclusion Criteria:

  • Moderate or severe intellectual disability.
  • Cognitive impairment on the Screen for Cognitive Impairment in Psychiatry, Spanish version (SCIP-S), defined as a total score below the 5th percentile or any subscale score below the 3rd percentile according to clinical-sample norms adjusted for age and educational level.
  • Active psychotic episode.
  • Language barrier preventing completion of the assessments or participation in the group sessions.
  • Previous participation in the Phase 1 usability pilot of the study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Andy's Mind serious game

Participants attend 8 weekly group sessions of 45 minutes (4 to 6 participants per group) using the Andy's Mind psychoeducational card game, led by trained mental health professionals.

Analog psychoeducational card game for 2 to 6 players, co-designed with mental health professionals and a person with lived experience of psychosis. Psychotic symptoms are represented as creatures that players stabilize using treatment and protective factors while facing relapse risks. 104 cards in seven categories (symptom, treatment, side effect, protection, attack/relapse, boom and wild cards), with text in Spanish, English and Arabic. Sessions 1-2: introduction to rules and cards. Sessions 3-8: gameplay followed by 5-10 minutes of questions to check understanding.

アクティブコンパレータ:Conventional psychoeducation

Participants attend 8 weekly group sessions of 45 minutes (4 to 8 participants per group) of conventional psychoeducation based on the PIENSA program, covering the same topics as the experimental arm.

Structured group psychoeducation based on the PIENSA program. Session 1: what is psychosis. Sessions 2-3: symptoms. Session 4: treatments. Session 5: side effects. Session 6: drugs and psychosis. Session 7: relapse prevention, protective and precipitating factors. Session 8: review and questions.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Insight into mental disorder (Scale to Assess Unawareness of Mental Disorder, SUMD)
時間枠:Baseline and immediately after the 8-week intervention

Insight assessed with the Spanish version of the SUMD, a clinician-rated semi-structured interview that evaluates awareness of having a mental disorder, awareness of the effects of medication and awareness of the social consequences of the disorder, plus awareness and attribution of 17 specific symptoms. Items are scored from 1 (aware) to 5 (unaware); higher scores indicate lower insight. Between-group comparison of post-intervention scores adjusted for baseline.

Baseline and immediately after the 8-week intervention
Attitudes toward antipsychotic medication as an indicator of treatment adherence (Drug Attitude Inventory, DAI-10)
時間枠:Baseline and immediately after the 8-week intervention

Self-reported attitudes and beliefs about psychiatric medication assessed with the Spanish version of the 10-item Drug Attitude Inventory (DAI-10). Each item is scored +1 or -1; total score ranges from -10 to +10, with higher scores indicating more positive attitudes toward medication. Between-group comparison of post-intervention scores adjusted for baseline.

Baseline and immediately after the 8-week intervention

二次結果の測定

結果測定
メジャーの説明
時間枠
Maintenance of insight (SUMD) at follow-up
時間枠:Baseline and 2 months after the end of the intervention

SUMD scores as described for the primary outcome, compared between groups at 2-month follow-up adjusted for baseline. Higher scores indicate lower insight.

Baseline and 2 months after the end of the intervention
Maintenance of attitudes toward medication (DAI-10) at follow-up
時間枠:Baseline and 2 months after the end of the intervention

DAI-10 total score (range -10 to +10; higher scores indicate more positive attitudes toward medication), compared between groups at 2-month follow-up adjusted for baseline.

Baseline and 2 months after the end of the intervention
Psychotic symptom severity (Positive and Negative Syndrome Scale, PANSS)
時間枠:Baseline, immediately after the 8-week intervention, and 2 months after the end of the intervention

Clinician-rated severity of positive, negative and general psychopathology symptoms assessed with the 30-item PANSS. Each item is scored from 1 (absent) to 7 (extreme); total score ranges from 30 to 210, with higher scores indicating greater symptom severity. Total and subscale scores will be analyzed.

Baseline, immediately after the 8-week intervention, and 2 months after the end of the intervention
Attitudes toward alcohol (Escala de Actitudes hacia el Alcohol, ESACAL)
時間枠:Baseline, immediately after the 8-week intervention, and 2 months after the end of the intervention

Self-reported attitudes toward alcohol assessed with the 13-item ESACAL, rated on a 5-point Likert scale (total score range 13 to 65). Items unfavorable to health are reverse-scored, so higher scores indicate attitudes more favorable to health.

Baseline, immediately after the 8-week intervention, and 2 months after the end of the intervention
Attitudes toward other drugs (Escala de Actitudes hacia otras Drogas, ESACDRO)
時間枠:Baseline, immediately after the 8-week intervention, and 2 months after the end of the intervention

Self-reported attitudes toward drugs other than alcohol assessed with the 13-item ESACDRO, rated on a 5-point Likert scale (total score range 13 to 65). Items unfavorable to health are reverse-scored, so higher scores indicate attitudes more favorable to health.

Baseline, immediately after the 8-week intervention, and 2 months after the end of the intervention
Satisfaction and engagement with the intervention
時間枠:Immediately after the 8-week intervention

Self-reported satisfaction and engagement with the intervention assessed with an ad hoc questionnaire rated on a 5-point Likert scale (1 to 5), with higher scores indicating greater satisfaction. Compared between groups.

Immediately after the 8-week intervention

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Andrea Fontán Abeijón, RN, BSc、Parc Sanitari Sant Joan de Déu

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年2月16日

一次修了 (推定)

2027年9月1日

研究の完了 (推定)

2027年12月1日

試験登録日

最初に提出

2026年11月12日

QC基準を満たした最初の提出物

2026年11月12日

最初の投稿 (実際)

2026年11月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年11月12日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • PIC-29-23
  • PR-623/2023 (その他の助成金/資金番号:Col.legi Oficial d'Infermeres i Infermers de Barcelona (COIB))
  • P202311 (その他の助成金/資金番号:Parc Sanitari Sant Joan de Déu / Institut de Recerca Sant Joan de Déu)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified individual participant data underlying the results reported in publications (sociodemographic variables and SUMD, DAI-10, PANSS, ESACAL, ESACDRO and satisfaction scores) will be available upon reasonable request. Because the sample includes people in prison mental health settings, a vulnerable population, data will not be deposited in an open repository and will only be shared under a data sharing agreement, for purposes consistent with the informed consent.

IPD 共有時間枠

Beginning 6 months after publication of the main results and for 5 years thereafter.

IPD 共有アクセス基準

Researchers who provide a methodologically sound proposal approved by an ethics committee may request access by contacting the principal investigator. Access requires approval by the sponsor (Fundació per a la Recerca i la Docència Sant Joan de Déu) and the signing of a data sharing agreement in compliance with the EU General Data Protection Regulation.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する